United Therapeutics (NASDAQ:UTHR) PT Raised to $121.00 at Credit Suisse Group

Share on StockTwits

United Therapeutics (NASDAQ:UTHR) had its price objective hoisted by research analysts at Credit Suisse Group from $113.00 to $121.00 in a report released on Thursday, The Fly reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Credit Suisse Group’s target price would indicate a potential upside of 16.13% from the stock’s previous close.

Several other research firms have also weighed in on UTHR. Zacks Investment Research lowered shares of United Therapeutics from a “hold” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research note on Thursday, January 2nd. Bank of America began coverage on shares of United Therapeutics in a research note on Tuesday, December 3rd. They issued an “underperform” rating and a $80.00 price objective on the stock. Wedbush reiterated a “buy” rating and issued a $237.00 price objective on shares of United Therapeutics in a research note on Monday, February 3rd. ValuEngine lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 4th. Finally, BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. United Therapeutics has an average rating of “Hold” and an average target price of $116.17.

United Therapeutics stock opened at $104.19 on Thursday. The firm has a market cap of $4.57 billion, a PE ratio of -48.01, a P/E/G ratio of -1.57 and a beta of 1.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.91 and a current ratio of 4.11. The firm’s 50 day moving average price is $92.81 and its two-hundred day moving average price is $87.21. United Therapeutics has a twelve month low of $74.31 and a twelve month high of $128.94.

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Amundi Pioneer Asset Management Inc. lifted its position in United Therapeutics by 18.8% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 76,221 shares of the biotechnology company’s stock valued at $8,945,000 after purchasing an additional 12,087 shares during the period. State of Alaska Department of Revenue lifted its position in United Therapeutics by 67.6% in the third quarter. State of Alaska Department of Revenue now owns 7,796 shares of the biotechnology company’s stock valued at $621,000 after purchasing an additional 3,145 shares during the period. Pacer Advisors Inc. acquired a new stake in United Therapeutics in the third quarter valued at about $1,257,000. Nisa Investment Advisors LLC lifted its position in United Therapeutics by 18.3% in the third quarter. Nisa Investment Advisors LLC now owns 23,610 shares of the biotechnology company’s stock valued at $1,883,000 after purchasing an additional 3,649 shares during the period. Finally, Envestnet Asset Management Inc. lifted its position in United Therapeutics by 26.2% in the third quarter. Envestnet Asset Management Inc. now owns 8,965 shares of the biotechnology company’s stock valued at $715,000 after purchasing an additional 1,863 shares during the period. Institutional investors own 93.26% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

See Also: Percentage Decliners

The Fly

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.